[Advances in the treatment of chronic lymphocytic leukaemia]

Abstract

Chronic lymphocytic leukemia (CLL), a proliferation of mature B cells, is one of the most prevalent haematological malignancies. Progress has been made in its treatment during the last few decades, and chemoimmunotherapy based on fludarabine, cyclophosphamide and rituximab is considered the treatment of choice for patients with standard-risk CLL and good performance status. However, due to the characterization of high-risk biological subgroups and its presentation in elderly patients and/or with comorbidities, targeted therapies, such as B-cell receptor inhibitors, have been developed and approved during the last few years. The current review examines traditional therapeutic strategies and focuses on new small molecules that already represent promising elements of the CLL treatment landscape.

Keywords: B-cell receptor; Chemoimmunotherapy; Chronic lymphocytic leukemia; Ibrutinib; Idelalisib; Inmunoquimioterapia; Leucemia linfocítica crónica; Receptor del linfocito B.